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Alpha 1-antitrypsin (AAT) deficiency is a genetic disorder that primarily affects the lungs and liver. While AAT deficiency is one of 
the most common genetic disorders in the Caucasian population, it is extremely rare in Asians. Here, we report the case of a 36-
year- old Korean woman with AAT deficiency who visited the emergency department of our hospital for the treatment of progres-
sive dyspnea that had begun 10 years ago. She had never smoked. Chest computed tomography revealed panlobular emphysema 
in both lungs, which suggested AAT deficiency. The serum AAT level was 33 mg/dL (reference interval: 90-200 mg/dL). Four exons 
of the SERPINA1 gene, which is responsible for AAT deficiency, and their flanking regions were analyzed by PCR-direct sequencing. 
The patient was found to have 1 missense mutation (c.230C>T, p.Ser77Phe; Siiyama) and 1 frameshift mutation (c.1158dupC, p.Glu387-
ArgfsX14; QOclayton). This is the first Korean case of AAT deficiency confirmed by genetic analysis and the second case of a compound 
heterozygote of Siiyama and QOclayton, the first case of which was reported from Japan.
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Alpha 1-antitrypsin (AAT) is a serine protease inhibitor 
encoded by the SERPINA1 gene. The protein is synthesized 
in the liver and circulates in serum to reach its target organs 
including the lungs. It inhibits various proteases and pro-
tects alveolar tissue against neutrophil elastase, thereby pre-
venting destruction of these tissues. In patients with defec-
tive SERPINA1 genes, i.e., patients with AAT deficiency, the 
uninhibited elastase may damage the alveoli and cause early-
onset emphysema. Moreover, abnormally folded and poly-
merized AAT may remain in hepatocytes, thereby forming 
intracellular inclusions and inducing liver injury [1, 2].
PiZ and PiS, which are considered as the products of the 
major alleles responsible for AAT deficiency, show consid-
erable ethnic differences. PiZ is the most common deficient 
variant, especially in Northern and Western Europe, with 
plasma levels less than 50 mg/dL in homozygotes, whereas 
PiS is more frequent in the Mediterranean population with 
plasma levels about 60% of normal [1]. The estimated gene 
frequencies of PiZ and PiS in Koreans were 0.0061 and 0.0031, 
respectively, which were significantly lower than those ob-
served in Caucasians. About 7,000 individuals are expected 
to have deficient allele combinations [2]. However, there 
have been no reports yet on AAT deficiency in Korea. In 
this report, we present a case of AAT deficiency in a Korean 
woman and elucidate her genetic characteristics.
CASE REPORT
A 36-year-old woman visited our emergency department 
with progressive dyspnea. The patient started experiencing 
dyspnea on exertion 10 years ago, and the condition exacer-
bated gradually. After experiencing pneumonia 3 months 
ago, her symptoms worsened and her daily activities were Ko D-H, et al.  •  AAT Deficiency in a Korean Patient
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restricted. Two weeks before the visit, she experienced sym-
ptoms of upper respiratory tract infection (intermittent fe-
ver, cough, sputum, and sore throat) and dyspnea, which 
was observed even when the patient was in a resting state. 
Chest computed tomography revealed diffuse severe pan-
lobular emphysema in both lungs, which suggested AAT 
deficiency (Fig. 1). Pulmonary function tests showed a se-
vere obstructive pattern with positive bronchodilator re-
sponse, increased residual volume, and decreased diffusing 
capacity. Serum AAT levels, measured by using nephelom-
etry (BNII, Siemens Healthcare Diagnostics Inc., Newark, 
DE, USA), significantly decreased to 33 mg/dL (reference 
interval: 90-200 mg/dL). She had never smoked nor did she 
show a definite risk of environmental exposure to harmful 
dusts or noxious gases. Physical examination and laboratory 
findings showed no evidence of hepatic dysfunction.
We suspected AAT deficiency and performed genetic anal-
ysis of the SERPINA1 gene. All 4 coding exons of the SER-
PINA1 gene and their flanking regions (NC_000014.8, NM_ 
00102235.2) were analyzed by PCR-direct sequencing using 
primers reported in a previous study [3]. The allelic back-
bone of the SERPINA1 gene was M1 (Val237, numbered 
from a methionine at translation initiation site) and 2 se-
quence variations were identified-c.230C>T and c.1158-
dupC (Fig. 2). Substitution of cytosine by thymine leads to 
the substitution of serine by phenylalanine at codon 77 (p.Ser-
77Phe) and duplication of cytosine yields a frameshift muta-
tion with a premature stop codon (p.Glu387ArgfsX14). These 
variations were found in previous reports and corresponded 
to a deficient allele, Siiyama, and a null allele, QOclayton [4, 5].
The patient’s pedigree (Fig. 3) shows that the patient’s fa-
ther and son had the QOclayton alleles, and the patient inher-
ited the Siiyama allele from her mother and transferred it to 
her daughter. However, none of the patient’s siblings har-
bored the mutations. Serum AAT levels of the carriers, i.e., 
the parents and the children of the patients, were less than 
or approximately equal to the lower reference interval limit 
(65-100 mg/dL).
The patient is being treated with a bronchodilator and is 
scheduled to undergo lung transplantation.
DISCUSSION
A 36-year-old woman, without any risk factors developed 
severe emphysema and showed notably decreased AAT level 
in her serum. The patient was found to be a compound het-
erozygote for a substitution and a duplication mutation in 
the SERPINA1 gene.
The Siiyama allele, which is formed by a missense variation, 
was first described by Seyama et al. in a Japanese patient [4]. 
The substitution occurs in one of the conserved regions de-
termined by Huber and Carrell [6] and is thought to affect 
the three-dimensional structure of the protein. The Siiyama al-
lele is relatively prevalent in Japan [7]. 
Fig. 1. (A) Chest radiograph of the patient shows hyperinflated lungs. (B) Chest computed tomography of the patient at the initial visit. Bilateral diffuse emphy-
sema is observed in lungs. 
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Another duplicational variation causing a frameshift 
(c.1158dupC) was initially reported to yield a null allele, 
QOsaarbruecken, in the allele backbone of M1(Ala237) [8]. Our 
patient showed the same variation in M1 (Val237), and the 
resultant allele was designated as QOclayton [5]. In transfec-
tion studies, this allele may produce a normal amount of 
mRNA but the protein remains in rough endoplasmic re-
ticulum and cannot be secreted outside the cells [5].
We described the protein variations in a codon numbered 
from the methionine residue at the translation initiation 
site. However, the first 24 amino acids of AAT act as a signal 
peptide [9, 10], and therefore, many studies numbered the 
codon from the glutamic acid at the 25th position [5, 7, 11]. 
There is no consensus about this issue and many articles 
and/or databases designate the same variations with differ-
ent numbers [12, 13]. Therefore, careful attention should be 
paid when researchers report variations or cite other reports.
Measurement of serum AAT levels is a common proce-
dure and may be used as an initial screening test. However, 
several points should be considered when interpreting the 
results. First, different methods for AAT measurement have 
different reference intervals, with the values for radial im-
munodiffusion higher than those for nephelometry [1]. The 
techniques applied and their reference intervals should be 
considered when referring to other studies. Second, AAT is 
a positive acute phase reactant[14]. Some patients may pres-
ent with symptoms and/or signs of infection. Thus, estima-
tion of baseline levels may be difficult in some cases. Third, 
Fig. 2. The chromatogram obtained by sequencing of SERPINA1 gene. (A) A missense mutation (c.230C>T, p.Ser77Phe) corresponds to the Siiyama allele. (B) A frame-
shift mutation (c.1158dupC, p.Glu387ArgfsX14) indicates the QOclayton allele.
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Fig. 3. The patient’s pedigree. The proband is indicated by an arrow. The number below each individual represents the alpha-1antitrypsin level in serum (mg/dL; 
reference interval 90-200 mg/dL). The QOclayton allele is indicated by fully filled symbols and the Siiyama allele by the symbols filled with oblique lines. The parents and 
children of the patient were heterozygotes for Siiyama or QOclayton, as expected. NT represents not tested.Ko D-H, et al.  •  AAT Deficiency in a Korean Patient
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various combinations of normal alleles and deficient alleles 
may be associated with a borderline zone of AAT levels, and 
patients showing levels in this borderline zone should be 
subjected to further evaluation [1]. Finally, some patients 
may have dysfunctional alleles showing almost normal lev-
els and decreased functions of AAT [15, 16]. As a result, AAT 
levels should be interpreted cautiously, and the diagnosis of 
AAT deficiency should not be judged solely on the basis of 
serum AAT levels.
This is the second case of a compound heterozygote of 
S  iiyama and QOclayton; the first case was reported by a Japanese 
group [11]. The clinical, radiologic, and laboratory findings 
in their report are similar to those in our case, except for the 
smoking history. The early onset and severity of the disease 
in our case can be attributed to the significantly decreased 
levels of AAT, which was caused by the compound hetero-
zygous genotype of a deficient allele and a null allele.
In summary, we identified a case of AAT deficiency in 
Korea and studied the causative genetic variations. The pa-
tient was a compound heterozygote of Siiyama and QOclayton, 
and this genotype was responsible for the disease. A study 
of the patient’s pedigree showed that she had inherited 1 al-
lele from each parent. To the best of our knowledge, this is 
the first report of a genetically confirmed case of AAT defi-
ciency in Korea. The genetic constitutions of the SERPINA1 
gene in Koreans might be quite different from those in other 
races, and targeted mutation analysis for PiZ and/or PiS may 
not work efficiently. Analysis of the entire exons and their 
flanking regions may be needed for genetic analysis of the 
patients suspected to have AAT deficiency, until more cases 
reveal the genetic composition in Korea. 
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